Leqvio Pre-Surgery Hold Window: What Clinicians Need to Know About Inclisiran Perioperative Management

What Is the Official Pre-Surgery Hold Window for Inclisiran?

There is no FDA-mandated pre-surgery hold window for inclisiran. The FDA prescribing information for Leqvio does not list elective or emergent surgery as a contraindication, and no minimum washout period before a surgical procedure has been formally established in labeling. Clinicians therefore make perioperative decisions based on the drug's pharmacokinetic and pharmacodynamic profile rather than a specific calendar rule.

Why Plasma Half-Life Does Not Drive the Decision

Inclisiran's plasma half-life is short, approximately 9 hours after subcutaneous injection [1]. Within 48 hours of dosing, systemic drug concentrations fall below quantifiable levels. This sharply distinguishes inclisiran from monoclonal PCSK9 inhibitors such as evolocumab (Repatha) or alirocumab (Praluent), which have half-lives of 11 to 17 days and require conventional washout thinking.

The operative question for inclisiran is not "how long until the drug leaves the bloodstream?" It is "how long will LDL-C suppression persist?" The answer is the full 6-month dosing interval. Once the siRNA is delivered to hepatocytes, it continues silencing PCSK9 mRNA production for months, independent of circulating drug levels.

Hepatic siRNA Activity and Surgical Relevance

Inclisiran works by delivering a double-stranded siRNA into hepatocytes via a GalNAc conjugate. Inside the liver cell, the siRNA enters the RNA-induced silencing complex (RISC) and catalytically degrades PCSK9 mRNA [2]. RISC loading is not reversible through drug discontinuation. This means that even if a dose is withheld before surgery, LDL-C suppression continues for the remaining duration of the dosing interval. Withholding a scheduled dose has no meaningful short-term effect on the patient's lipid status during or immediately after the surgical procedure.

ORION Trial Data Relevant to Perioperative Planning

The ORION-10 and ORION-11 phase 3 trials, published in the New England Journal of Medicine in 2020, established the efficacy and safety profile that informs perioperative decision-making today [3].

ORION-10 Results at a Glance

ORION-10 enrolled 1,561 patients with atherosclerotic cardiovascular disease (ASCVD) who were already on maximum-tolerated statin therapy. At 510 days, inclisiran 284 mg SC produced a 52.3% reduction in LDL-C from baseline versus placebo (P<0.001) [3]. The time-averaged LDL-C reduction across the entire follow-up period was 53.8%, demonstrating that effect durability, not peak effect, is the clinical story.

ORION-11 Results and Safety Signal

ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents. Inclisiran produced a 49.9% reduction in LDL-C at day 510 versus placebo (P<0.001) [3]. Injection-site reactions occurred in 4.7% of inclisiran patients versus 0.5% on placebo. No hepatotoxicity signal, no elevation in liver enzymes, and no drug-drug interactions relevant to common anesthetic agents were identified. The trial's safety data did not flag surgery or anesthesia as a special concern.

These two trials together enrolled 3,178 patients and provided the foundational safety dataset that the FDA reviewed for labeling. Neither trial protocol required a pre-surgical hold, and surgical adverse events were not clustered in the inclisiran arm.

Pharmacokinetic Rationale for the No-Hold Approach

Understanding inclisiran's three-phase disposition explains why the no-hold approach is pharmacologically sound [1].

Phase 1: Rapid Distribution (0 to 4 Hours)

After subcutaneous injection, inclisiran is absorbed and distributes rapidly. Peak plasma concentration (Cmax) is reached at approximately 4 hours. At this stage, drug is entering hepatocytes via the ASGR1 receptor targeted by the GalNAc ligand.

Phase 2: Hepatic Uptake and RISC Loading (4 to 48 Hours)

The majority of clinical activity occurs here. GalNAc-mediated uptake concentrates inclisiran in liver parenchymal cells. Plasma levels decline steeply as drug partitions out of the central compartment. By 48 hours, plasma concentrations are negligible [1].

Phase 3: Sustained siRNA Effect (Weeks to 6 Months)

Once loaded into RISC, the antisense strand guides cleavage of PCSK9 mRNA. The catalytic nature of RISC means a single siRNA molecule may degrade multiple mRNA copies. This produces the prolonged pharmacodynamic effect observed in ORION trials, a 50% LDL-C reduction maintained across the full 180-day dosing interval, with no dose between day 90 and day 270 required [3].

From a surgical standpoint, this means a patient who received their scheduled inclisiran dose 3 months ago will have the same degree of PCSK9 inhibition on the day of surgery as they did at day 90. There is nothing to "hold."

Perioperative Cardiovascular Risk and LDL-C Targets

Guidelines from the American College of Cardiology and the American Heart Association recommend LDL-C below 70 mg/dL for patients with established ASCVD, and below 55 mg/dL for very high-risk patients, before major elective surgery [4]. Inclisiran reliably achieves these targets in the majority of patients already on maximally tolerated statin therapy.

Statins and Inclisiran in the Perioperative Window

The ACC/AHA 2022 perioperative cardiovascular evaluation guidelines advise continuing statin therapy through the perioperative period in patients already taking statins, citing reduced MACE risk [4]. Inclisiran is additive to statin therapy: in ORION-10, all patients were on background statins, and inclisiran produced an additional 52% LDL-C reduction on top of statin-achieved levels [3]. Stopping inclisiran before surgery would not lower LDL-C in the short term (because the siRNA effect persists), and there is no pharmacological rationale for doing so.

Acute Surgical Stress and Lipid Physiology

Major surgery induces an acute-phase response that can transiently raise or lower measured LDL-C due to changes in inflammatory cytokines, fluid shifts, and hepatic synthetic function [5]. This transient perturbation is independent of inclisiran's mechanism. Patients on inclisiran will still experience post-surgical LDL-C fluctuation, but their baseline suppression provides a protective buffer. A lipid panel drawn within 2 weeks of major surgery may not accurately reflect the patient's steady-state LDL-C; repeat measurement at 6 to 8 weeks post-operatively is more reliable for dose-response assessment.

When to Time the Next Inclisiran Dose Around Surgery

The standard inclisiran dosing schedule is Day 1, Day 90 (plus or minus 2 weeks), then every 6 months (plus or minus 2 weeks) [1]. Surgery does not require schedule modification. The 2-week flexibility window built into the label accommodates most planned procedures without any calendar adjustment.

Scenario 1: Scheduled Dose Falls Within 2 Weeks of Surgery

If the patient's next inclisiran dose falls within 14 days of a planned surgical date, the clinician has two options. First, administer the dose as scheduled, ideally at least 48 to 72 hours before surgery to allow the brief period of transient injection-site inflammation to resolve. Second, defer the dose by up to 2 weeks post-operatively, staying within the label's flexibility window. Either approach maintains full LDL-C suppression.

Scenario 2: Emergency Surgery Before Next Scheduled Dose

For urgent or emergent procedures, no action is required. LDL-C will be suppressed from the most recent dose. Post-operative redosing resumes on the original schedule once the patient is medically stable and able to attend the outpatient injection visit.

Scenario 3: Patient Is Hospitalized and Misses a Dose

Inclisiran is administered only by a healthcare professional in a clinical setting; it is not a self-injectable drug [1]. A hospitalized patient cannot self-dose. If the scheduled injection window (plus or minus 2 weeks) passes during hospitalization, the prescribing clinician should administer the dose at the next available outpatient visit. ORION trial data does not provide specific guidance on late dosing, but the pharmacodynamic durability of the previous dose means LDL-C suppression continues for weeks beyond the nominal 180-day window, though it will gradually wane [3].

Drug-Drug Interactions with Anesthetic and Surgical Agents

Inclisiran does not inhibit or induce cytochrome P450 enzymes. It is not a substrate of CYP enzymes, P-glycoprotein, or organic anion transporting polypeptides [1]. This distinguishes it from statin drugs, which interact with CYP3A4 substrates including several anesthetic agents. No clinically significant interactions between inclisiran and propofol, volatile anesthetics, opioids, neuromuscular blocking agents, or perioperative antibiotics have been identified.

Renal Considerations in Surgical Patients

Inclisiran is primarily cleared renally as intact drug and metabolic fragments [1]. In patients with severe renal impairment (eGFR <30 mL/min/1.73m2), inclisiran exposure is increased approximately 2-fold, but no dose adjustment is currently specified in the FDA label. Patients who experience acute kidney injury (AKI) perioperatively may have transiently elevated inclisiran exposure if a dose was given around the time of surgery, though no clinical harm signal from this has been reported. Clinicians should note renal function changes in the chart and discuss with nephrology if AKI is severe.

Hepatic Function and Surgical Risk

Inclisiran is delivered specifically to hepatocytes. Severe hepatic impairment (Child-Pugh C) has not been studied, and the FDA label advises caution [1]. Patients undergoing hepatic surgery or those with pre-existing cirrhosis warrant individualized assessment. In the ORION trials, patients with severe hepatic impairment were excluded, so formal efficacy and safety data in this subgroup are absent [3].

Practical Perioperative Checklist for Inclisiran Patients

Surgical teams and prescribing clinicians should coordinate the following before any major elective procedure in a patient on inclisiran.

Pre-Operative Steps

Confirm the date of the patient's last inclisiran injection and calculate the next scheduled dose window. Review the baseline LDL-C at 3 months post-last dose to confirm adequate response; a target of below 70 mg/dL in ASCVD patients aligns with ACC/AHA guidelines [4]. Verify that the patient's background statin is continued through the perioperative period per guidelines. No blood tests specific to inclisiran monitoring (such as PCSK9 levels) are required before surgery; clinical monitoring uses standard lipid panels.

Intra-Operative and Immediate Post-Operative Steps

Anesthesia teams do not need to make any adjustments for inclisiran. No interaction with standard anesthetic agents is expected. Document inclisiran on the medication reconciliation list so that post-operative providers are aware of the patient's lipid management plan.

Post-Operative Redosing

Resume inclisiran on the original schedule once the patient is medically stable and ambulatory enough to attend an outpatient visit. If the dose window has passed by more than 2 weeks, administer the next dose as soon as feasible; the 6-month clock resets from the actual administration date. Obtain a lipid panel 3 months after the rescheduled dose to confirm re-establishment of LDL-C target.

Guideline Context: What ACC/AHA and ESC Say About PCSK9 Inhibition Perioperatively

The 2022 ACC/AHA Guideline on Perioperative Cardiovascular Assessment and Management does not specifically address PCSK9 inhibitors or inclisiran, reflecting the relatively recent introduction of these agents into broad clinical practice [4]. The guideline's general principle is to continue lipid-lowering therapy perioperatively in patients with established ASCVD, which by extension supports uninterrupted inclisiran use.

The 2019 European Society of Cardiology/European Atherosclerosis Society dyslipidemia guidelines recommend LDL-C below 55 mg/dL for very high-risk patients and note that PCSK9 inhibitors should be considered in patients not reaching targets on maximally tolerated statin plus ezetimibe [6]. The ESC does not specify a perioperative hold for any PCSK9 inhibitor class.

"The evidence strongly supports continuing statin therapy in the perioperative period," states the ACC/AHA 2022 perioperative guideline [4]. While this language refers to statins, the same physiological logic applies to agents like inclisiran that work through a complementary and durable mechanism, since abrupt discontinuation provides no clinical benefit and risks worsening the patient's long-term cardiovascular risk management continuity.

Emerging Clinical Data: ORION-4 and Cardiovascular Outcomes

ORION-3 and ORION-4 are the long-term extension and outcomes trials for inclisiran [7]. ORION-4, a 15,000-patient randomized controlled trial conducted in the United Kingdom and registered with ClinicalTrials.gov (NCT03705234), is evaluating MACE outcomes with inclisiran versus placebo on background statin therapy. Results from ORION-4 are expected to provide outcomes data analogous to the FOURIER trial for evolocumab and the ODYSSEY OUTCOMES trial for alirocumab [8].

While outcomes data from ORION-4 remain pending full publication, the mechanism-of-action evidence and the ORION-10/11 LDL-C reduction data strongly support the cardiovascular protective rationale for maintaining inclisiran through surgical periods rather than interrupting therapy. The FOURIER trial (N=27,564) demonstrated that each 1 mmol/L (approximately 38.7 mg/dL) reduction in LDL-C with evolocumab produced a 15% relative risk reduction in MACE at 2.2 years [8]. Given that inclisiran produces comparable LDL-C reductions through PCSK9 inhibition via a different mechanism, these data are pharmacologically informative for context, even though direct outcomes evidence for inclisiran specifically is still accumulating [8].

Special Populations: Familial Hypercholesterolemia Patients Undergoing Surgery

Patients with heterozygous familial hypercholesterolemia (HeFH) may have baseline LDL-C values of 160 to 400 mg/dL prior to treatment. In ORION-9 (N=482, HeFH population), inclisiran produced a 39.7% LDL-C reduction from baseline at day 510 (P<0.001) [9]. For HeFH patients, maintaining inclisiran through the surgical period is especially important because these patients have lifelong elevated cardiovascular risk and LDL-C rebound after any therapy interruption could have disproportionate impact.

Homozygous FH (HoFH) patients represent an even higher-risk group. The FDA label notes that inclisiran's efficacy depends on functional LDL receptor activity; patients with receptor-negative HoFH had attenuated responses in clinical experience [1]. Surgical teams managing HoFH patients should consult with a lipid specialist regardless of inclisiran status.